SCHEMBL4300892

SCHEMBL4300892

CC(C)c1nnc2ccc(-c3oc(N)nc3-c3ccc(F)cc3F)nn12

nearest known ligand 0.62

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MAP4K4 O95819 7/20 0.62
CSNK1D P48730 7/20 0.62
PRKD2 Q9BZL6 6/20 0.62
PRKD3 O94806 6/20 0.62
MINK1 Q8N4C8 4/20 0.62
MAPK9 P45984 4/20 0.62
EGFR P00533 5/20 0.58
MAPK14 Q16539 13/20 0.48
ERBB2 P04626 1/20 0.41
MARK3 P27448 1/20 0.41
GSK3B P49841 1/20 0.41
DYRK1A Q13627 1/20 0.41
TAOK1 Q7L7X3 1/20 0.41
KDR P35968 1/20 0.39
CLK2 P49760 1/20 0.39
GSK3A P49840 1/20 0.39
SLK Q9H2G2 1/20 0.39
CLK4 Q9HAZ1 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9056922 0.82 MAP4K4 (0.64) MAP4K4CSNK1DPRKD2PRKD3MINK1
SCHEMBL4300842 0.82 MAP4K4 (0.64) MAP4K4CSNK1DPRKD2PRKD3MINK1
SCHEMBL4299756 0.81 MAP4K4 (0.58) MAP4K4CSNK1DPRKD2PRKD3MINK1
SCHEMBL8990765 0.79 MAP4K4 (0.56) MAP4K4CSNK1DPRKD2PRKD3MINK1
SCHEMBL4300074 0.78 MAP4K4 (0.60) MAP4K4CSNK1DPRKD2PRKD3MINK1
SCHEMBL3243415 0.78 MAP4K4 (0.57) MAP4K4CSNK1DPRKD2PRKD3MINK1
SCHEMBL4302811 0.78 MAP4K4 (0.59) MAP4K4CSNK1DPRKD2PRKD3MINK1
SCHEMBL4296478 0.77 MAP4K4 (0.59) MAP4K4CSNK1DPRKD2PRKD3MINK1
SCHEMBL4294018 0.77 MAP4K4 (0.59) MAP4K4CSNK1DPRKD2PRKD3MINK1
SCHEMBL4300444 0.77 MAP4K4 (1.00) MAP4K4CSNK1DPRKD2PRKD3MINK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8188083-B2 Triazolopyridazines ABBOTT LABORATORIES (US) 2012-05-29 US disclosed
US-8188083-B2 Triazolopyridazines ABBOTT LABORATORIES (US) 2012-05-29 US disclosed
US-8188083-B2 Triazolopyridazines ABBOTT LABORATORIES (US) 2012-05-29 US disclosed
US-20090270402-A1 Novel triazolopyridazines ABBVIE INC. 2009-10-29 US disclosed
US-20090270402-A1 Novel triazolopyridazines ABBVIE INC. 2009-10-29 US disclosed
US-20090270402-A1 Novel triazolopyridazines ABBVIE INC. 2009-10-29 US disclosed
WO-2009005675-A1 NOVEL TRIAZOLOPYRIDAZINES ABBOTT LABORATORIES (US) 2009-01-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090270402-A1 Novel triazolopyridazines MAP3K5, MAP3K1, MAP3K2 MAP4K4 24/4885CSNK1D 173/4885PRKD2 76/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.